Pooled analysis with cumulative exposure to teriflunomide >6800 patient-years.
Safety and tolerability data consistent with results from individual studies.
No new or unexpected safety signals identified.
Most events mild-to-moderate and infrequently led to treatment discontinuation.
Both doses of teriflunomide had similar and manageable safety profiles.